12/25/2023 0 Comments Silverback therapeutics phone![]() ![]() “We are pleased to partner with Orbital’s team of industry leaders and visionaries in drug development to help them achieve a bold mission of bringing forward the next generation of RNA-based medicines.” Orbital was founded and has been built to be that special company,” said Kristina Burow, managing partner at ARCH Venture Partners, co-founder and board director of Orbital. “Few companies can possess the know-how, technology and biologic insights to deliver on the full breadth of opportunity that RNA medicines could provide for patients. We are thrilled to have the backing of such an exceptional group of investors, whose support further enables the growth of our organization and the meaningful expansion of our platform and portfolio.” “Since our founding, we have been diligently focused on advancing our platform of RNA technologies to elucidate the most promising opportunities with our initial programs so we may reach patients as efficiently as possible. ![]() “In recent years, we have only just started to see the expansive potential RNA-based therapeutics may offer to the future of medicine and how we treat disease,” said Giuseppe Ciaramella, Ph.D., Orbital co-founder and CEO. This platform is designed to extend the durability of Orbital’s novel RNA therapeutics, while also expanding their delivery to a wide range of cell types and tissues. The company is building a first-in-kind RNA platform that integrates both established and emerging RNA technologies and delivery mechanisms. Orbital Therapeutics aims to expand the applicability of RNA-based medicines across a range of human diseases, including in the areas of next-generation vaccines, immunomodulation, and protein replacement. The Series A raise was led by ARCH Venture Partners, with participation from initial investors a16z Bio + Health and Newpath Partners, and new investors Abu Dhabi Growth Fund (ADG), Redmile Group, Exor N.V., Invus, Moore Strategic Ventures, iGlobe Platinum Fund Group, Casdin Capital, Agent Capital, Alexandria Venture Investments, Rellim Capital Management, Heritage Medical Systems, and other undisclosed investors. Orbital Therapeutics, a company focused on enhancing global health by unleashing the full potential of RNA medicines to treat human disease, today announced the successful closing of $270 million Series A financing. Industry Veterans Niru Subramanian Appointed as Chief Operating Officer and Jonathan Piazza Appointed as Chief Financial Officer Financing Supports Advancement of an Industry-leading, Comprehensive Platform of RNA Technologies and a First-in-Class Portfolio of Programmable RNA Therapeutics ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |